Abstract:Mutation in the telomerase reverse transcriptase promoter (TERTp )is commonly observed in various malignancies, such as central nervous system (CNS) tumors, malignant melanoma, bladder cancer, and thyroid carcinoma. These mutations are recognized as significant poor prognostic factors for these tumors. In this investigation, a total of 528 cases of adult-type diffuse gliomas diagnosed at a single institution were reclassified according to the 2021 WHO classifications of CNS tumors, 5th edition (WHO2021). The study analyzed clinicopathological and genetic features, including TERTp mutations in each tumor. The impact of known prognostic factors on patient outcomes was analyzed through Kaplan–Meier survival and Cox regression analysis. TERTp mutations were predominantly identified in 94.1% of oligodendrogliomas (ODG), followed by 66.3% in glioblastoma, IDH-wildtype (GBM-IDHwt), and 9.2% of astrocytomas, IDH-mutant (A-IDHm). When considering A-IDHm and GBM as astrocytic tumors (Group 1) and ODGs (Group 2), TERTp mutations emerged as a significant adverse prognostic factor (p = 0.013) in Group 1. However, within each GBM-IDHwt and A-IDHm, the presence of TERTp mutations did not significantly impact patient prognosis (p = 0.215 and 0.268, respectively). Due to the high frequency of TERTp mutations in Group 2 (ODG) and their consistent prolonged survival, a statistical analysis to evaluate their impact on overall survival was deemed impractical. When considering MGMTp status, the combined TERTp-mutated and MGMTp-unmethylated group exhibited the worst prognosis in OS (p = 0.018) and PFS (p = 0.034) of GBM. This study confirmed that the classification of tumors according to the WHO2021 criteria effectively reflected prognosis. Both uni- and multivariate analyses in GBM, age, MGMTp methylation, and CDKN2A/B homozygous deletion were statistically significant prognostic factors while in univariate analysis in A-IDHm, grade 4, the Ki-67 index and MYCN amplifications were statistically significant prognostic factors. This study suggests that it is important to classify and manage tumors based on their genetic characteristics in adult-type diffuse gliomas.

TERT Genetic Mutations as Prognostic Marker in Glioma

Tert Mutation in Glioma: Frequency, Prognosis and Risk

Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis

Paradoxical Prognostic Impact of TERT Promoter Mutations in Gliomas Depends on Different Histological and Genetic Backgrounds.

TERT Promoter Mutations and Long Telomere Length Predict Poor Survival and Radiotherapy Resistance in Gliomas

Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.

RETRACTED ARTICLE: Relationships Between PTEN Gene Mutations and Prognosis in Glioma: a Meta-Analysis

Telomerase Reverse Transcriptase (TERT) Rs2736100 Polymorphism Contributes to Increased Risk of Glioma: Evidence from a Meta-Analysis.

TERT rs2853676 polymorphisms correlate with glioma prognosis in Chinese population.

TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas

TERT Mutations-Associated Alterations in Clinical Characteristics, Immune Environment and Therapy Response in Glioblastomas

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma

Prognostic stratification of patients with primary glioblastoma based on mutations of TERT promoter and IDH1

TERT Promoter Mutations Contribute to Subset Prognostication of Lower-Grade Gliomas

The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

Clinical Characteristics And Prognostic Significance Of Tert Promoter Mutations In Cancer: A Cohort Study And A Meta-Analysis

Association of Telomerase Reverse Transcriptase Promoter Mutations with Clinicopathological Features and Prognosis of Thyroid Cancer: a Meta-Analysis.

Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis

Human TERT promoter mutations as a prognostic biomarker in glioma

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy